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Local anesthetics are used routinely and effectively. However, many are also known to activate neurotoxic pathways. We tested the
neuroprotective efficacy of ginkgolide B (GB), an active component of Ginkgo biloba, against ROS-mediated neurotoxicity caused
by the local anesthetic bupivacaine. SH-SY5Y cells were treated with different concentrations of bupivacaine alone or following
preincubation with GB. Pretreatment with GB increased SH-SY5Y cell viability and attenuated intracellular ROS accumulation,
apoptosis, mitochondrial dysfunction, and ER stress. GB suppressed bupivacaine-induced mitochondrial depolarization and
mitochondria complex I and III inhibition and increased cleaved caspase-3 and Htra2 expression, which was strongly indicative of
activation of mitochondria-dependent apoptosis with concomitantly enhanced expressions of Grp78, caspase-12 mRNA, protein,
and ER stress. GB also improved ultrastructural changes indicative ofmitochondrial and ER damage induced by bupivacaine.These
results implicate bupivacaine-induced ROS-dependent mitochondria, ER dysfunction, and apoptosis, which can be attenuated by
GB through its antioxidant property.
1. Introduction
Local anesthetics are among the most common clinical drugs
and are generally regarded as safe [1, 2]. However, they have
also been shown to be neurotoxic even at normal clinical
dose [3, 4]. This neurotoxicity is mediated at least in part
by activation of apoptotic pathways [5, 6]. In the cauda
equina, intrathecally administered local anesthetics induced
cell swelling, atrophy, edema, axonal degeneration, and the
appearance of myelin ovoids as well as macrophage infiltra-
tion [7]. These morphological signs of degeneration indicate
that local anesthetics can initiate a complex cascade of direct
cytotoxic and ensuing inflammatory responses, although the
molecular mechanisms of local anesthetic toxicity are still
largely unknown.
Local anesthetics have been shown to induce neural
dysfunction and apoptosis in vitro [8–11]. For example, bupi-
vacaine may inhibit mitochondrial respiratory complexes I
and III, leading to decreased ATP production, collapse of the
mitochondrial membrane potential (Δ𝜓m), overproduction
of reactive oxygen species (ROS), and ultimately liberation
of cytochrome c and activation of the caspase-3-dependent
apoptosis pathway [10–12]. In fact, ROS accumulation, mito-
chondrial uncoupling, and depolarization of 𝜓m are among
the earliest indicators of apoptosis induced by local anesthet-
ics [13, 14]. In addition tomitochondrial damage, dysfunction
of the endoplasmic reticulum (ER) stress has also been
implicated in apoptosis. Arai and Nonaka et al. proposed that
oxidative stress associated with local anesthetics can induce
Ca2+ release from intracellular stores, including the rough
endoplasmic reticulum (rER) [11, 15]. Loss of intraluminal
Ca2+ may lead to ER stress [16], further, ROS generation,
[17] and activation of ER-dependent apoptosis pathways [18].
Thus, mitochondrial and ER damage associated with ROS
overproduction may act synergistically to evoke cell death
in response to bupivacaine or other structurally related local
anesthetics.
Ginkgo biloba has been used in traditional Chinese
medicine for thousands of years. Evidence accumulated over
the last decade suggests that concentrated and partially
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Figure 1: Proliferation effects of bupivacaine on SH-SY5Y cells and GB weakened bupivacaine-induced cell injury in SH-SY5Y cells. (a) Cells
were incubated in the presence or absence of various concentrations of bupivacaine for 24 h (∗𝑃 < 0.05 versus control group). Cell growth
was determined by the MTT assay. (b) Cell viability was decreased by treatment with 1mmol/L bupivacaine for 24 hours. Decreased viability
was inhibited by GB pretreatment for 6 hours, except for cells treated with 5𝜇mol/L GB (∗𝑃 < 0.05 versus nonpretreated group). Each data
point represents the mean ± SD of 6 separate experiments.
purified extracts of Ginkgo biloba leaves may afford pro-
tection against certain neurological diseases [19]. Indeed,
ginkgolide B (GB), the major active component of Ginkgo
biloba extract, has been used to treat degenerative dementia
and neurosensory disorders [20]. Even for children, GB is a
safe drug without adverse reactions [21]. Furthermore, GB
reduced the level of ROS in vivo, suggesting that the raw
extract contains antioxidants [22].Therefore, GBmay protect
neurons against the neurotoxicity of local anesthetics like
bupivacaine by reducing oxidative stress.
The principal aims of this study were to examine the
molecular mechanisms of bupivacaine toxicity and the neu-
roprotective efficacy of GB in vitro.
2. Materials and Methods
2.1. Materials. The human neuroblastoma cell line SH-SY5Y
was purchased from the Shanghai Institutes for Biological
Sciences. Bupivacaine hydrochloride (purity 99.9%) was
purchased from Sigma (St. Louis, MO, USA). Ginkgolide B
(purity≥ 99.5%)was obtained from theNational Institutes for
Food and Drug Control and dissolved in dimethyl sulfoxide
(DMSO) (KeyGEN, China). Other reagents used included
DMEM/F12 medium and fetal bovine serum (Gibco,
USA), 5,5󸀠, 6,6󸀠-tetrachloro-1,1󸀠, 3,3󸀠-tetraethyl tetrethyl
benzimidalyl carbocyanine iodide (JC-1), 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2-tetrazolium bromide (MTT), 2󸀠,7󸀠-
dichlorofluorescein diacetate (DCFH-DA), mitochondrial
isolation agent and mitochondrial storage solution (all from
Beyotime, China), anti-Grp78 and anti-caspase-12 (Abgent,
USA), anti-cleaved caspase-3 and anti-HtrA2 (Abcam, UK),
anti-GAPDH antibody (Goodhere, China), and Annexin
V-FITC and propidium iodide (KeyGEN, China). The
cell counting Kit-8 (CCK8) was purchased from Dojindo
(Dojindo, Kumamoto, Japan). All reagents were obtained
from commercial suppliers and were of standard biochemical
quality.
2.2. Cell Culture. Cells of the SH-SY5Y line were cultured
in DMEM/F12 medium supplemented with 15% fetal bovine
serum, 100U/mLpenicillin, and 100𝜇g/mL streptomycin and
maintained in a humidified 5% CO
2
incubator at 37∘C. The
media were changed every 2 days.
2.3. MTT Assay. The effect of bupivacaine on the number
of viable SH-SY5Y cells was determined by the MTT assay.
Cells were seeded onto 96-well plates at 5 × 103 cells/well
with 100𝜇L of culture medium and treated with various con-
centrations of bupivacaine as indicated below. Treated cells
were incubated with 20𝜇L MTT at 37∘C for 4 h, the medium
removed, and 150𝜇L DMSO added to dissolve the formazan
crystals produced from MTT by viable cells. The optical
density (OD) of the homogenous purple formazan/DMSO
solutions was measured using a spectrophotometer (Bio-Tek,
USA) at 570 nm.
2.4. CCK-8 Assay. Cells were seeded onto 96-well plates at
5 × 103 cells/well in 100𝜇L culture medium. In pilot experi-
ments to determine the working range of GB, cultures were
pretreated with 5–40 𝜇mol/L GB in new media for 6 h or
subjected to a control media change prior to treatment with
1mmol/L bupivacaine for 24 h (the half-maximal neurotoxic
dose according to [23]). After bupivacaine treatment, 10 𝜇L of
CCK-8was added to eachwell for another 3 h at 37∘C.TheOD
was read at 450 nm using a spectrophotometer.
2.5. Apoptosis Assay by Flow Cytometry. Cells were seeded
onto 24-well plates at 5 × 105 cells/well in 500𝜇L culture
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Figure 2: GB pretreatment decreased the number of apoptotic cells induced by bupivacaine. ((a)–(e)) Cells were treated with 0, 5, 10, 20, and
40𝜇mol/L GB for 6 hours, respectively, prior to treatment with 1mmol/L bupivacaine for 24 h. (f) Summarized data show apoptotic rate as
detected by flow cytometry. Data represented are the mean ± SD of 6 separate experiments (∗𝑃 < 0.05 versus 0 𝜇mol/L GB).
medium. After control or GB pretreatment and bupivacaine
administration as described, the cells were rinsed with PBS,
harvested, and resuspended in 500𝜇L binding buffer. To this
cell suspensionwas added 5𝜇LAnnexinV-FITC (amarker of
early apoptosis) and 5𝜇L propidium iodide (a marker of late
apoptosis). After 10min incubation, cell apoptosis was deter-
mined by flow cytometry (BD FACS Calibur, USA).
2.6. Measurement of Reactive Oxygen Species. Cells were
seeded onto 24-well plates at 5 × 105 cells/well in 500𝜇L
culture medium and divided into four treatment groups: (i)
untreated controls (Con), (ii) cells treated with 1mmol/L
bupivacaine for 24 h (Bup), (iii) cells pretreated with
40 𝜇mol/L GB for 6 h, and (iv) cells treated with 40𝜇mol/L
GB for 6 h prior to 1mmol/L bupivacaine exposure for 24 h
(GB+Bup). Intracellular accumulation of ROSwas estimated
using the redox-sensitive fluorescent dye DCFH-DA. The
cells were incubated with 10𝜇mol/L DCFH-DA at 37∘C dur-
ing the last 20min of Con, Bup, GB, or GB + Bup treatment.
Treated and DCFH-DA-stained cells were washed 3 times
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Figure 3: The levels of reactive oxygen species were measured by flow cytometry. GB pretreatment decreased ROS overproduction induced
by bupivacaine. Summarized data shows the Geo mean of ROS as detected by flow cytometry. Data represented are mean ± SD of 6 separate
experiments (∗𝑃 < 0.01).
in PBS, harvested, and resuspended in PBS. Fluorescent
signal intensitywas determined by flow cytometry to estimate
relative ROS accumulation.
2.7. Mitochondrial Membrane Potentials Assay. Mitochon-
drialmembrane potential (𝜓m)depolarization, an early event
in the mitochondrial apoptosis cascade, was measured fluo-
rometrically using JC-1. Briefly, cells cultured in 6-well plates
and treated as described for the ROSmeasurementwere incu-
batedwith JC-1 staining solution (5𝜇g/mL) at 37∘C for 20min
and rinsed twice with PBS. Mitochondrial membrane poten-
tial was estimated by measuring the fluorescence ratio of free
JC-1 monomers (green) to JC-1 aggregates in mitochondria
(red) by dual emission fluorescence microscopy (Nikon
ECLIPSE TE2000-u, Japan) and flow cytometry. Mitochon-
drial depolarization is indicated by an increase in the propor-
tion of cells emitting green fluorescence.
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Figure 4: GB attenuated the bupivacaine-induced decline of mitochondrial membrane potential (Δ𝜓m). SH-SY5Y cells were treated with
bupivacaine for 24 hours in the presence or absence of GB. (a) SH-SY5Y cells were observed using fluorescent microscopy. (b) Δ𝜓m were
detected by flow cytometry (c) Δ𝜓m expressed as the ratio of red fluorescence over green fluorescence. Data represented are the mean ± SD
of 6 separate experiments (∗𝑃 < 0.01).
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Figure 5: GB attenuated bupivacaine-induced decrease in the
activity of mitochondrial complexes I and III. Experiments were
repeated 6 times, and the data were presented as the mean ± SD
(∗𝑃 < 0.01).
2.8. Isolation of Mitochondrial. Mitochondria were isolated
from SH-SY5Y cells cultured in 6-well plates and treated
as described for ROS measurements. After rinsing twice in
PBS, cells were harvested, centrifuged at 600×g for 5min at
4∘C, and then homogenized in 1mL mitochondria isolation
reagent until 50% of the cells were lysed. Homogenates were
centrifuged at 600×g for 5min at 4∘C to remove large debris
and unlysed cells. The supernatant containing mitochondria
then transferred to another centrifuge tube, and mitochon-
dria precipitated by centrifugation at 11,000×g for 10min
at 4∘C. After centrifugation, the pellet was resuspended in
mitochondrial storage solution.
2.9. Measurement of Respiratory Complex I and Complex III
Activities. The activities of respiratory chain complexes I and
III were determined according to the methods as described
by Zhang et al. [24]. All assays were performed at 25∘C
in a final volume of 1mL using a spectrophotometer. To
release complexes from the mitochondrial membrane, iso-
latedmitochondriawere subjected to three freeze-thaw cycles
(25∘C to −25∘C) in hypotonic media (25mmol/L potassium
phosphate, 5mmol/LMgCl
2
, pH 7.2) before activitymeasure-
ments.The enzyme activity was expressed in nanomolars per
minute per milligram protein.
2.10. Western Blotting. Cells were incubated as described for
the ROS measurements, harvested, and lysed in lysis buffer.
After centrifugation, the soluble protein concentration in
the supernatant was determined by a BCA Protein Assay
Kit (Beyotime, China). Protein samples were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
Table 1: qRT-PCR primers.
Gene Primers
18srRNA Forward: 5
󸀠-CCT GGA TAC CGC AGC TAG GA-3󸀠
Reverse: 5󸀠-GCG GCG CAA TAC GAA TGC CCC-3󸀠
GRP78 Forward: 5
󸀠-TGC AGC AGG ACA TCA AGT TC-3󸀠
Reverse: 5󸀠-CGC TGG TCA AAG TCT TCT CC-3󸀠
Caspase-12 Forward: 5
󸀠-GGA GAA AGA GAG GCG AAC AT-3󸀠
Reverse: 5󸀠-CCT GGA TAC CGC AGC TAG GA-3󸀠
(20𝜇g/lane), electrotransferred to polyvinylidene difluoride
(PVDF) membranes. Membranes were blocked with 5%
nonfat drymilk inTris-buffered saline and then immunoblot-
ted with anti-Grp78 (1 : 500), anti-caspase-12 (1 : 500), anti-
cleaved caspase-3 (1 : 500), anti-HtrA2 (1 : 500), or anti-
GAPDH antibody (1 : 1000, as the gel loading control)
overnight at 4∘C. All antibodies were diluted in Tris-HCl-
buffered saline containing 5% nonfat dry milk and 0.1%
Tween-20. After rinsing, immunolabeled membranes were
incubated with horseradish peroxidase (HRP) conjugated
anti-rabbit immunoglobulin (1 : 1000) for 1 h. Specific pro-
teins were detected by enhanced chemiluminescence and
exposure to X-ray film. Bands were quantified by scanning
the films. The expression levels of Grp78, caspase-12, cleaved
caspase-3, and HtrA2 protein were normalized to GAPDH.
2.11. Quantitative Real Time PCR (qRT-PCR). To investigate
the effect of bupivacaine on ER stress, we examined Grp78
and caspase-12mRNA expression levels by qRT-PCR. Total
RNA was isolated using an RNA Isolation Kit (Qiagen,
USA) according to the manufacturer’s instructions. DNase
I (TAKARA, Japan) was used to remove DNA from total
RNA. cDNA was synthesized using a cDNA Synthesis Kit
(Promega, USA), and theMaxima SYBRGreen qPCRMaster
Mix (2X) (Fermentas, USA) was used to quantify gene
expression. Conditions for amplification and quantification
included initial denaturing (50∘C for 2 minutes and 95∘C for
10 minutes) followed by 40 cycles of 2 amplification stages
(95∘C for 15 seconds and 60∘C for 1 minute) for primer
annealing and elongation. A dissociation stage (95∘C for 15
seconds, 60∘C for 1 minute, and 95∘C for 15 seconds) was
added at the end of amplification stage to ensure that a single
amplicon was produced and to validate the primer pairs.
Reactions were performed in triplicate. Relative expression
levels of caspase-12 and Grp78 mRNA were quantified using
the 2-ΔΔCT method [25, 26] and 18 srRNA as the normaliz-
ing gene. The primers used are listed in Table 1.
2.12. Transmission Electron Microscopy (TEM). Neuroblas-
toma cells treated as described for the ROS measurements
were harvested, washed once with PBS, fixed in 2.5% glu-
taraldehyde at 4∘C for 1 h, postfixed in 1% osmic acid for
30min, and stained with lead uranium. Cell ultrastructure
was observed under a transmission electron microscope
(Hitachi-600, Japan).
2.13. Statistical Analysis. All values are expressed as means ±
SD. Multiple comparisons between groups were analyzed by
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Figure 6: Htra2 induction and cleaved caspase-3 activation were detected by Western blot. Experiments were repeated three times, and the
data were presented as mean ± SD (∗𝑃 < 0.01; #𝑃 < 0.05).
one-way ANOVA. LSD was performed as post hoc analysis
for multiple comparisons between groups. A 𝑃 < 0.05 was
considered significant.
3. Results
3.1. Bupivacaine Reduced Cell Viability. The effect of bupi-
vacaine on the viability of SH-SY5Y neuroblastoma cells
was first examined using the by MTT assay. Bupivacaine
(1, 1.5, 2mmol/L) significantly reduced viable cell number
compared to controls (Figure 1(a)). We then estimated viable
cell number at multiple time points during treatment with
1mmol/L bupivacaine, the LD50 measured in a previous
study [23]. Compared to controls, bupivacaine reduced viable
cell number at all time points between 24 and 48 h. Thus,
bupivacaine reduced SHSY5Y cell proliferation, induced cell
death, or both.
3.2. GB Attenuated Cell Toxicity Induced by Bupivacaine. In
our pilot experiment, treatment with 5–40𝜇mol/L GB for
6 h did not affect cell proliferation. The antiproliferative or
cytotoxic effect of 1mmol/L bupivacaine was then compared
between GB-pretreated (5–40𝜇mol/L) and GB-na¨ıve cul-
tures using the CCK-8 assay. Cell counts were higher at all GB
doses except at 5 𝜇mol/L, the lowest dose tested (Figure 1(b)).
To determine if GB actually protected SHSY5Y cells against
bupivacaine-mediated cytotoxicity, apoptosis was examined
by flow cytometry.
3.3. GB Attenuated Bupivacaine-Induced SH-SY5Y Cell Apop-
tosis. Ginkgolide B pretreatment decreased bupivacaine-
induced apoptosis as evidenced by reduced Annexin V+/PI−
and Annexin V+/PI+ cell numbers (representing early or late
apoptosis, resp.) at 40 𝜇mol/L GB (Figure 2). The reduction
was similar for both Annexin V+/PI− and Annexin V+/PI+
cell populations, indicating that GB blocked the initiation of
apoptosis.
3.4. GB Attenuated ROS Production Induced by Bupiva-
caine. Treatment with 1mmol/L bupivacaine increased the
intracellular ROS accumulation, indicated by DCFH-DA
fluorescence,whileGBpretreatment significantly reduced the
ROS-dependent fluorescent signal (Figure 3). These results
suggest that GB acts to preserve mitochondrial function,
elevates endogenous antioxidant capacity, and (or) possesses
inherent antioxidant activity.
3.5. GB Inhibited Mitochondrial Depolarization Induced by
Bupivacaine. The mitochondrial membrane potential (𝜓m)
is correlated with functional activity, while loss of 𝜓m (depo-
larization) is indicative of mitochondrial uncoupling and is
an early sign of apoptosis. We estimated 𝜓m in SH-SY5Y
cells by the shift in JC-1 fluorescence (from red to green).
Exposure to 1mmol/L bupivacaine resulted in 𝜓m dissipa-
tion, while GB pretreatment preserved 𝜓m during bupiva-
caine exposure (Figure 4). These results suggest that GB
may prevent apoptosis by preserving mitochondrial function
and by preventing activation of mitochondrial-dependent
apoptosis.
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Figure 7: Grp78 and caspase-12 mRNA expression as detected by
qRT-PCR. Experimentswere repeated three times, and the datawere
presented as the mean ± SD (∗𝑃 < 0.01, #𝑃 < 0.05).
3.6. Preservation of Mitochondrial Respiratory Complex I and
III Activity by GB. The activities of mitochondrial complexes
I and III were significantly reduced by bupivacaine, sug-
gesting potential loss of oxidative phosphorylation. Again,
disruption of mitochondrial function was reversed by GB
pretreatment (Figure 5).
3.7. The Level of Cleaved Caspase-3 and HtrA2. Mitochon-
drial uncoupling and 𝜓m depolarization are associated with
a dramatic increase in mitochondrial inner membrane per-
meability and the release of factors (e.g., cytochrome c and
HtrA2) that initiate or regulate apoptotic pathways. West-
ern blots (Figure 6) revealed significantly elevated cleaved
(activated) caspase-3 and HtrA2 expression in bupivacaine-
treated cultures compared to controls, an effect that was
suppressed by GB pretreatment.
3.8. GB Reduced ER Stress Induced by Bupivacaine. Expres-
sion of Grp78 and caspase-12 is indicative of ER stress. Quan-
titative RT-PCR andWestern blots revealed enhanced Grp78
and caspase-12 mRNA (Figure 7) and protein expression
levels (Figure 8) in BG-na¨ıve bupivacaine-treated cells com-
pared to controls, responses that were reversed by GB
pretreatment.
3.9. Morphological Changes of Cells. Normal healthy SH-
SY5Y cells were round and regular, with typically shaped
ER and mitochondrial membranes in TEM images (Fig-
ure 9(a)). After exposure to bupivacaine for 24 h, the ER
appeared swollen and degranulated, while mitochondria
were swollen with loss of internal membrane structure
(Figure 9(b)). Cells treated with 40 𝜇mol/L GB showed a
nearly normal ultrastructure (Figure 9(c)), indicating that
GB had little endogenous toxicity or physiological effects
on ER or mitochondrial function. Cells pretreated with GB
prior to bupivacaine exposure resembled controls at the
ultrastructural level, with only slight expansion of the ER
(Figure 9(d)). This preservation of ER and mitochondrial
structure strongly suggests that GB protected SH-SY5Y cells
against bupivacaine-induced mitochondrial and ER damage.
4. Discussion
Ginkgolide B (GB), an active component of the traditional
medicinal herb Ginkgo biloba, protected SH-SY5Y cells from
bupivacaine-induced injury. Pretreatment with 40𝜇mol/L
GB suppressed bupivacaine-induced mitochondrial depolar-
ization, mitochondria complex I and III inhibition, ROS
accumulation, ER stress, and apoptosis. These results impli-
catemitochondrial dysfunction and ER stress in bupivacaine-
induced apoptosis and highlight GB as a potential neuropro-
tectant against bupivacaine toxicity through its antioxidant
property.
The therapeutic time window is critical in defining
the potential clinical utility of any neuroprotective agent.
Ginkgolide B has been shown to exert significant protective
effect in cerebral ischemia injury up to 2 h following intra-
venous administration after reperfusion in rat [27]. In our
pilot experiment, pretreatment with 5–40𝜇mmol/L GB for
2 h, 4 h could not protect SH-SY5Y cells from bupivacaine
neurotoxicity, which is different from other people’s previous
research. Only 6 h duration of pretreatment with GB con-
ferred protective effect; therefore, 6 h treatment protocol was
used in our study.
Oxidoredox homeostasis is essential for cellular survival.
Overproduction of ROS leads to oxidative stress and plays an
important role in the process of apoptosis in many cell types
[28], which can be ameliorated by endogenous and exogenous
antioxidants. Bupivacaine was shown to induce ROS genera-
tion in SH-SY5Y cells [6], while GB reduced ROS levels in
vivo [22], suggesting that GBmay protect against bupivacaine
toxicity by suppressing ROS accumulation. Bupivacaine did
substantially increase ROS, amajor initiator of apoptosis [29],
while preincubation with GB suppressed ROS accumulation
and many of the biochemical and morphological signs of
oxidative stress. To investigate the potential reasons for
increased ROS production, we measured the activities of
mitochondrial complexes I and III, the main generators of
ROS [30]. The activity of both complexes decreased after
bupivacaine treatment, while GB pretreatment partially
reversed this effect. By preserving oxidative phosphorylation,
GB maintained 𝜓m and decreased ROS production associ-
ated with mitochondrial uncoupling. Aside from mitochon-
drial dysfunction, however, ROS may also be generated by
calcium-dependent protease activity, nNOS, and acidosis,
the contributions of which were not examined and warrant
further study as possible mechanisms of bupivacaine toxicity.
Besides energy production via the electron transport
chain, mitochondria are responsible for several other impor-
tant cellular functions, including the initiation and regulation
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Con GBBup
30kDa
78kDa
36kDa
Caspase-12
Grp78
GAPDH
2.00
1.50
1.00
0.50
0.00
Con Bup GB GB + Bup
∗ #
∗ #
Con Bup GB GB + Bup
GB + Bup
Ca
sp
as
e-
12
/G
A
PD
H
 p
ro
te
in
2.00
1.50
1.00
0.50
0.00
G
rp
78
/G
A
PD
H
 p
ro
te
in
Error bars: ±1SD Error bars: ±1SD
Figure 8: Grp78 and caspase-12 expression representing ER stress as detected by Western blot. Experiments were repeated three times, and
the data were presented as the mean ± SD (∗𝑃 < 0.01, #𝑃 < 0.05).
(a) (b)
(c) (d)
Figure 9: Morphologic changes of SH-SY5Y cells. (a) Cells in the control group retained a normal ultrastructure; (b) cells in the Bup group
contained degranulated rER, swollen Mt, and hazy mitochondrial structures; (c) treatment with GB resulted in and showed a nearly normal
structure; (d) pretreatment with GB represented slight expansion of ER.
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of apoptosis [31]. Local anesthetics may dissipate 𝜓m and
activate caspases, leading to apoptotic cell death [6, 32]. In
our study, apoptotic cell death induced by bupivacaine was
associated with 𝜓m depolarization, and both bupivacaine-
induced apoptosis and 𝜓m dissipation were attenuated by
GB. The HtrA2 protein is a serine protease that acts as a
proapoptotic factor following release from themitochondrial
matrix through large nonselective pores (permeability tran-
sition pores, mPTPs) that can be opened by overproduction
of ROS [33, 34]. Release of mitochondrial HtrA2 into the
cytoplasm was inhibited by the caspase inhibitor z-VAD-fmk
[34, 35], suggesting that caspase activation may precede and
possibly induce HtrA2 release. Increased cleaved caspase-3 is
associatedwithmitochondria-dependent apoptosis following
sustained loss of 𝜓m [36]. Thus, bupivacaine likely induced
apoptosis by reducingmitochondria complex activity, leading
to overproduction of ROS, collapse of the mitochondrial
membrane potential, release of proapoptotic factors from the
mitochondrial matrix, and subsequent caspase-3 activation.
ES stress may activate alternate apoptotic pathways or
exacerbate mitochondria-dependent apoptosis. The ER is
critical for protein synthesis and folding, lipid and sterol syn-
thesis, and calcium homeostasis. Stressors such as hypoxia,
glucose deprivation, and calcium depletion from the ER
lumen lead to ER dysfunction [37], resulting in cellular
calcium dysregulation, protein misfolding and aggregation,
and activation of proapoptotic effectors such as caspase-12.
Bupivacaine caused ER stress as evidenced by elevated
caspase-12 and Grp78 expression, and this stress may have
resulted from ROS accumulation as reported by Takahashi
et al. [17].
Grp78 is a well-characterized indicator of UPR activation
(the unfolded protein response) and a critical protectant
against ER stress by preventing protein aggregation [38].
However, when the ER stress is severe or prolonged, the
increase in Grp78 is no longer sufficient to prevent apoptosis,
and theUPR switches from a cytoprotective to a proapoptotic
response involving activation of specific effector proteins
such as caspase-12, which is activated only by ER stress-
initiated apoptotic pathways [37]. In accordance with pre-
vious studies [39, 40], Grp78 expression was upregulated in
parallel with caspase-12, indicative of ER stress and ER stress-
specific apoptosis. Ginkgolide B inhibited the overexpression
of Grp78 and caspase-12, suggesting that suppression of
cell death resulted from disruption of both mitochondrial
and ER-dependent apoptotic pathways. This conclusion was
further corroborated by TEM images showing reduced
organelle swelling andmaintenance of ER andmitochondrial
membrane integrity in cells pretreated with GB prior to
bupivacaine.
Some limitations of this study should be noted. First,
we examined doses of bupivacaine (1mmol/L or 0.03%)
that are not clinically relevant, as local injections often use
0.25% or 0.5%, although the duration of exposure was greatly
prolonged in this study. Second, these in vitro results from
transformed neuroblastoma cells may not be applicable to
neurons in vivo. Nonetheless, previous results have demon-
strated morphological signs of oxidative stress and apop-
tosis following local anesthetic administration in vivo, and
exogenous antioxidants (like GB) have well-established neu-
roprotective efficacy.
In summary, the current study suggests that bupivacaine
elicits ROS production, which in turn triggers mitochondrial
depolarization, mitochondria-dependent apoptosis, and ER
stress. These pathological responses were reduced or ame-
liorated by pretreatment with ginkgolide B. These results
provide novel insights into themolecularmechanisms under-
lying the neurotoxicity of bupivacaine and highlight GB as a
prototype treatment for the neurotoxicity elicited by this class
of local anesthetics.
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